AAPGAscentage Pharma Group Inc.Signing up patients
A Study of Olverembatinib in SDH-deficient GIST.
GIST
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 40 (planned)
- Started
- Nov 11, 2024
- Main results expected
- Mar 31, 2027
- Fully finished
- Jun 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival(PFS) rate
Measured over: 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06640361 · record last updated 2026-07-23 · checked 2026-11-09 15:47 UTC